3DTwin® Technology

Identifying effective cancer therapies

Precision oncology is a rapidly evolving field that seeks to develop individualized cancer treatments based on a patient’s specific cancer subtype. PreComb’s 3DTwin platform is a promising innovation in this area, as it aims to address the gap between the discovery of effective cancer therapies and their availability to patients.

3DTwin® Screen

3DTwin Screen

3DTwin® Automation


3DTwin® Digital

3DTwin Digital

Clinical network

Clinical network

Our game-changing technology is poised to transform precision oncology by enabling the rapid discovery and delivery of personalized cancer treatments. With our proprietary screening and automation technology, we’re helping to speed up the drug discovery process and bring new therapies to patients faster than ever before. In combination with our advanced digitalization framework, we’re unlocking insights from massive amounts of clinical data, empowering clinicians to make the right treatment decisions.

In summary, with PreComb’s 3DTwin® technology, we have the opportunity to enhance the efficiency and impact of cancer treatment by harnessing advanced technology and data analysis methods. As we actively participate in the ongoing evolution of precision oncology, embracing and driving forward innovations like these will be crucial in our collective efforts to combat cancer.

Background information about functional personalized oncology

Over the years, the medical field has made great strides in providing personalized and targeted therapies for patients. This progress has given rise to precision medicine, an approach that utilizes the distinct genetic, molecular, and cellular features of an individual’s disease to design the most effective treatment plan. Traditional precision medicine has seen remarkable successes in certain cases, such as the development of targeted therapies for specific cancer subtypes. However, as the limitations of these conventional methods become increasingly evident, a new and promising approach has emerged: functional drug profiling. Early clinical results have demonstrated its impressive potential to predict patient therapies, paving the way for a new era in precision medicine.